Stocks and Investing Stocks and Investing
Mon, July 24, 2023

Matt Miksic Maintained (ABT) at Buy with Increased Target to $132 on, Jul 24th, 2023


Published on 2024-10-28 05:02:51 - WOPRAI, Matt Miksic
  Print publication without navigation


Matt Miksic of Barclays, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $127 to $132 on, Jul 24th, 2023.

Matt has made no other calls on ABT in the last 4 months.



There are 10 other peers that have a rating on ABT. Out of the 10 peers that are also analyzing ABT, 3 agree with Matt's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Lewis of "Morgan Stanley" Reiterated at Hold and Held Target at $112 on, Friday, July 21st, 2023
  • Anthony Petrone of "Mizuho" Initiated at Hold with Increased Target to $115 on, Friday, July 21st, 2023
  • Mike Polark of "Wolfe Research" Upgraded from Sell to Hold on, Friday, July 21st, 2023


These are the ratings of the 7 analyists that currently disagree with Matt


  • Matthew Korn of "UBS" Maintained at Strong Buy with Increased Target to $130 on, Thursday, April 20th, 2023
  • Jayson Bedford of "Raymond James" Maintained at Buy with Increased Target to $123 on, Thursday, April 20th, 2023
  • Joanne Wuensch of "Citigroup" Maintained at Strong Buy with Increased Target to $130 on, Thursday, April 20th, 2023
  • Ryan Zimmerman of "BTIG" Maintained at Strong Buy with Increased Target to $130 on, Monday, April 17th, 2023
  • Lawrence Biegelsen of "Wells Fargo" Maintained at Buy with Decreased Target to $136 on, Monday, April 10th, 2023
  • Larry Biegelsen of "Wells Fargo" Maintained at Buy with Decreased Target to $136 on, Wednesday, April 5th, 2023
  • Danielle Antalffy of "UBS" Initiated at Strong Buy and Held Target at $117 on, Wednesday, March 29th, 2023

Contributing Sources